Bemnifosbuvir hemisulfate NEW
| Price | $53 | $118 | $193 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-12-02 |
Product Details
| Product Name: Bemnifosbuvir hemisulfate | CAS No.: 2241337-84-6 |
| Purity: 99.98% | Supply Ability: 10g |
| Release date: 2025/12/02 |
Product Introduction
Bioactivity
| Name | Bemnifosbuvir hemisulfate |
| Description | Bemnifosbuvir hemisulfate (AT-527) is a potent inhibitor of HCV virus replication. |
| In vitro | The potent in vitro activity of AT-511, the free base of bemnifosbuvir hemisulfate, against several coronaviruses, including SARS-CoV-2. In normal human airway epithelial cells, the concentration of AT-511 required to inhibit replication of SARS-CoV-2 by 90% (EC90) was 0.47?μM, very similar to its EC90 against human coronavirus (HCoV)-229E, HCoV-OC43, and SARS-CoV in Huh-7 cells[1]. |
| In vivo | When given orally to rats and monkeys, bemnifosbuvir hemisulfate preferentially delivered high levels of AT-9010 in the liver in vivo.These favorable preclinical attributes support bemnifosbuvir hemisulfate may increase SVR rates[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (3.96 mM), Sonication is recommended. DMSO : 170 mg/mL (269.60 mM), Sonication is recommended. |
| Keywords | SARS-CoV-2 | SARS-CoV | SARSCoV | SARS coronavirus | phosphoramidate | pangenotypic | nucleotide | Inhibitor | inhibit | Hepatitis C virus | HCVProtease | HCV Protease | HCV | guanosine | Bemnifosbuvir Hemisulfate | Bemnifosbuvir hemisulfate | Bemnifosbuvir | AT527 | AT 527 | antiviral |
| Inhibitors Related | Nirmatrelvir | EIDD-1931 | Methyl 2-amino-5-bromobenzoate | Remdesivir | Ribavirin | Silymarin | Molnupiravir | Umifenovir hydrochloride | Hydroxychloroquine | Chloroquine phosphate | Artemisinin | Dexamethasone |
| Related Compound Libraries | Bioactive Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library | Nucleotide Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1kg |
VIP1Y
|
Hefei Lbao Physical & Chemical Science Co.,Ltd
|
2025-09-18 | |
| $33.00/50mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-12-03 | |
| $2.20/1000kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-09-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY